RedHill Biopharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for RedHill Biopharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	22.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks

Jul 28

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Nov 24

RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency

Oct 18

RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Dec 02

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RedHill Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:RDHL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	7	24	-36	-36	N/A
9/30/2023	19	34	-29	-29	N/A
6/30/2023	36	12	-26	-26	N/A
3/31/2023	52	-1	-32	-32	N/A
12/31/2022	62	-72	-29	-29	N/A
9/30/2022	71	-92	-42	-42	N/A
6/30/2022	75	-78	-55	-55	N/A
3/31/2022	78	-95	-57	-57	N/A
12/31/2021	86	-98	-65	-65	N/A
9/30/2021	85	-98	-63	-63	N/A
6/30/2021	84	-95	-54	-54	N/A
3/31/2021	84	-82	-103	-50	N/A
12/31/2020	64	-76	-102	-49	N/A
9/30/2020	44	-64	-104	-50	N/A
6/30/2020	25	-55	-102	-48	N/A
3/31/2020	6	-50	-45	-44	N/A
12/31/2019	6	-42	-41	-41	N/A
9/30/2019	6	-38	-35	-35	N/A
6/30/2019	7	-39	-35	-35	N/A
3/31/2019	8	-39	-33	-32	N/A
12/31/2018	8	-39	-35	-34	N/A
9/30/2018	9	-42	-40	-40	N/A
6/30/2018	8	-47	-44	-43	N/A
3/31/2018	6	-47	-45	-44	N/A
12/31/2017	4	-46	-46	-45	N/A
9/30/2017	2	-43	N/A	-41	N/A
6/30/2017	1	-37	N/A	-38	N/A
3/31/2017	0	-32	N/A	-34	N/A
12/31/2016	0	-29	N/A	-28	N/A
9/30/2016	0	-28	N/A	-24	N/A
6/30/2016	0	-22	N/A	-20	N/A
3/31/2016	0	-22	N/A	-19	N/A
12/31/2015	0	-21	N/A	-18	N/A
9/30/2015	0	-20	N/A	-18	N/A
6/30/2015	0	-21	N/A	-18	N/A
3/31/2015	0	-19	N/A	-17	N/A
12/31/2014	7	-11	N/A	-12	N/A
9/30/2014	7	-9	N/A	-9	N/A
6/30/2014	7	-7	N/A	-7	N/A
3/31/2014	7	-5	N/A	-5	N/A
12/31/2013	0	-11	N/A	-8	N/A
9/30/2013	0	-11	N/A	-8	N/A
6/30/2013	0	-10	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RDHL's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if RDHL's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if RDHL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RDHL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if RDHL's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RDHL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

RedHill Biopharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus forecasts updated

RedHill Biopharma Ltd. Provides Earnings Guidance for the Third Quarter Ended September 30, 2022

Consensus forecasts updated

Price target decreased to US$13.60

Forecast breakeven date moved forward to 2023

Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021

Recent updates

RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Full year 2023 earnings released: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $1.25 million.

New minor risk - Financial data availability

Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million.

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million.

Investor sentiment deteriorates as stock falls 15%

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Investor sentiment deteriorates as stock falls 22%

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034

Investor sentiment improves as stock rises 615%

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034

RedHill Biopharma Ltd. announced that it has received $4.043808 million in funding

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Redhill Biopharma Ltd. Announces Fda Snda Approval for Talicia®?

RedHill Biopharma Ltd. Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA)

New minor risk - Earnings quality

Second quarter 2023 earnings released

RedHill Biopharma Ltd. Announces its Partner, Gaelan Medical LLC Receives Marketing Approval from United Arab Emirates Ministry of Health for Talicia

RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks

New major risk - Share price stability

RedHill Biopharma Ltd., Annual General Meeting, Aug 08, 2023

First quarter 2023 earnings released: EPS: US$20.00 (vs US$15.64 loss in 1Q 2022)

New major risk - Revenue and earnings growth

RedHill Biopharma Ltd. Provides R&D Update

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Redhill Biopharma Ltd. Announces Board Changes

Full year 2022 earnings released: US$48.00 loss per share (vs US$84.03 loss in FY 2021)

Redhill Biopharma Ltd. Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 for Oncology Support

RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome

RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease

Redhill Biopharma Ltd. Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB 107 in Non-Hospitalized COVID-19

RedHill Biopharma Ltd. has completed a Composite Units Offering in the amount of $7.989775 million.

RedHill Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of $8 million.

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.46 loss in 3Q 2021)

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Consensus forecasts updated

Redhill Biopharma Ltd. Announces Positive New Data with Opaganib for Nuclear Radiation Injury

Insufficient new directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

RedHill Biopharma Ltd. Provides Earnings Guidance for the Third Quarter Ended September 30, 2022

RedHill Biopharma Ltd. Presents New Talicia® Data Analyses At Obesity Week 2022

Insufficient new directors

Redhill Biopharma Ltd. Announces Presentation of New Data Analyses for Talicia

RedHill Biopharma Ltd. Announces Grant of New COVID-19 Treatment Patent for its Oral Broad-Acting Antiviral, Opaganib

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency

Redhill Biopharma Ltd. Announces Study Results Showing in Vitro Efficacy Against the Currently Dominant Omicron Covid-19 Sub-Variant BA.5

Insufficient new directors

RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease

Consensus forecasts updated

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.53 loss in 1Q 2021)

RedHill Biopharma Ltd. to Report Q1, 2022 Results on Jun 23, 2022

Price target decreased to US$13.60

RedHill Presents New Talicia Data Analyses at DDW 2022

RedHill: Given Up For Dead

Forecast breakeven date moved forward to 2023

RedHill Biopharma Ltd. Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

RedHill Biopharma Ltd., Annual General Meeting, May 12, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

Price target decreased to US$14.14

RedHill Biopharma: Looking At An Unexciting Dead-End

RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI